Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department

Abstract

In a long-term real-life setting, drug survival of ustekinumab is better than that of TNF-a inhibitors for both biologic-naive and biologic-experienced patients with psoriasis.

Long‐term, real‐world efficacy of biologics for psoriasis: a single centre's experience

“…Prospectively collected registry data in the U.K., primarily from the British Association of Dermatologists Biologics and Immunomodulators Register, and focused on biologic‐naive patients with psoriasis, demonstrate that survival of response with biologic therapies decreases over time from 77% in the first year to 53% in the third year . Studies in other countries have shown similar results …”

Long-Term Infliximab Treatment in Psoriasis Patients: A National Multicentre Retrospective Study

“…e mean age at IFX introduction was 58.7 (32-83), and IFX was introduced as a late line of systemic therapy (mean 4.5 lines). e mean duration of IFX treatment was 8.5 years (6)(7)(8)(9)(10)(11)(12). In terms of comorbidities, dyslipidemia was observed in 15 patients (35%), and depressive disorders were treated in 13 patients (30%).…”

“…Although the prevalence of long-term IFX-treated patients is not known, previous studies demonstrated a drug survival of IFX inferior to 20% at 6 years [4,6]. In our series, we calculated a prevalence of 14% of patients who were treated with IFX for longer than 6 years.…”

“…In a real-world analysis of 16,545 biologic-naïve patients, Sbidian et al [4] found a prevalence of solid cancer in 2.9% of IFX-treated patients with a 3.6 years mean follow-up. In a practical real-life 12-year experience including 77 psoriasis patients treated with IFX [6], 2.6% patients developed solid cancer after a mean follow-up of 4.1 years. Although it was difficult to attribute these cancers to the long-term use of IFX, our data suggest that long-term pharmacovigilance is still required.…”

Псориатическая Нефропатия: Сущность, Спектр Клинических Проявлений И Доказательства Поражения Почек При Псориазе

“…В лечении псориаза тяжелой и средней степени тяжести успешно используются биологические агенты, прежде всего ингибиторы ФНО-α: инфликсимаб, адалимумаб, этанерцепт [59]. Данные, касающиеся неблагоприятных почечных эффектов в ответ на биологическую терапию, включают единичные описанные клинические случаи аутоиммунного поражения почек у пациентов с различными заболеваниями, включая псориаз [60,61].…”